Claire Mazumdar is CEO at Bicara Therapeutics Inc. (BCAX). They have made 2 open-market trades across 1 company since 2025, most recently 2026-08-10.
CIK 0002034671
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BCAX | 362,152 | $6.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BCAX | SELL · 10b5-1 | 2026-08-10 | 2026-08-12 | $27.98 | $280K | -3.2% | -6.2% | — |
| BCAX | SELL · 10b5-1 | 2026-07-10 | 2026-07-14 | $28.42 | $284K | -3.7% | -15.7% | -38.2% |
| BCAX | SELL · 10b5-1 | 2026-05-18 | 2026-05-20 | $20.04 | $301K | -2.7% | +21.7% | +23.6% |
| BCAX | SELL · 10b5-1 | 2026-04-20 | 2026-04-20 | $23.61 | $354K | -6.7% | -11.8% | +17.0% |
| BCAX | SELL · 10b5-1 | 2026-03-18 | 2026-03-20 | $18.82 | $565K | +10.2% | +26.2% | +24.9% |
| BCAX | SELL | 2026-03-09 | 2026-03-11 | $19.17 | $705K | -6.6% | +7.3% | +4.5% |
| BCAX | SELL | 2026-03-04 | 2026-03-06 | $18.74 | $154K | +0.8% | +14.1% | +11.6% |
| BCAX | SELL · 10b5-1 | 2025-11-24 | 2025-11-25 | $18.86 | $1.6M | +2.7% | -8.7% | -10.9% |
| BCAX | SELL · 10b5-1 | 2025-10-16 | 2025-10-20 | $18.83 | $908K | +0.9% | -6.9% | +2.5% |
| BCAX | SELL · 10b5-1 | 2025-10-13 | 2025-10-15 | $18.88 | $934K | -10.4% | -22.1% | -7.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.